In the week of December 8, 2025, 18 holders filed a new Schedule 13D and 68 a new Schedule 13G reporting 5% or more of a company. The largest stake reported that week is Ryuichi Sasaki's 96.15% of CTW Cayman (Schedule 13G, December 8, 2025).
New 13D18
New 13G68
Stated intents0
The week of 2025-12-08, 18 holders filed a new Schedule 13D and 68 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-12-08 | Envoy Medical, Inc. | Glen A. Taylor | 44.2% | SCHEDULE 13D |
| 2025-12-09 | InterCure Ltd. | Alexander Rabinovich | 29.4% | SCHEDULE 13D |
| 2025-12-12 | Westin Acquisition Corp. | Westin Investment Co. Ltd. | 27.9% | SCHEDULE 13D |
| 2025-12-11 | W R Berkley Corp | WR Berkley & Others LLC | 25.14% | SCHEDULE 13D |
| 2025-12-12 | 374Water Inc. | Nagar Yaacov | 19% | SCHEDULE 13D |
| 2025-12-10 | Psyence Biomedical Ltd. | KAOS Capital Ltd. | 16.77% | SCHEDULE 13D |
| 2025-12-08 | Powerdyne International, Inc. | Read Arthur M II | 15.4% | SCHEDULE 13D |
| 2025-12-11 | W R Berkley Corp | Mitsui Sumitomo Insurance Co., Ltd. | 12.8% | SCHEDULE 13D |
| 2025-12-11 | Silvia, Inc. | Anthony Pompliano | 12.4% | SCHEDULE 13D |
| 2025-12-09 | Pacific Coast Oil Trust | Eriksen Capital Management LLC | 11.7% | SCHEDULE 13D |
| 2025-12-12 | Chicago Rivet & Machine Co | Morrissey John A | 10.1% | SCHEDULE 13D |
| 2025-12-10 | Hudson Technologies Inc | Hartree Partners, LP | 8.7% | SCHEDULE 13D |
| 2025-12-12 | Freenome, Inc. | RA Capital Management, L.P. | 8.4% | SCHEDULE 13D |
| 2025-12-08 | Yatra Online, Inc. | Dhruv Shringi | 7.17% | SCHEDULE 13D |
| 2025-12-08 | Powerdyne International, Inc. | Madison Linda | 6.4% | SCHEDULE 13D |
| 2025-12-08 | Provectus Biopharmaceuticals, Inc. | Dominic Rodrigues | 5.67% | SCHEDULE 13D |
| 2025-12-08 | Carver Bancorp Inc | Detyga LLC | 5.3% | SCHEDULE 13D |
| 2025-12-09 | Clough Global Equity Fund | Saba Capital Management, L.P. | 5.06% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-12-08 | CTW Cayman | Ryuichi Sasaki | 96.15% | SCHEDULE 13G |
| 2025-12-11 | Pgim Etf Trust | Intrua Financial, LLC | 32% | SCHEDULE 13G |
| 2025-12-10 | First Trust Exchange-Traded Fund IV | Strategic Planning Group, LLC | 25.3% | SCHEDULE 13G |
| 2025-12-11 | Orla Mining Ltd | V. Prem Watsa | 19.8% | SCHEDULE 13G |
| 2025-12-12 | Central Bancompany, Inc. | The Central Trust Bank | 19.49% | SCHEDULE 13G |
| 2025-12-12 | Knorex Ltd. | Franklin Capital Enterprise Ltd | 17.1% | SCHEDULE 13G |
| 2025-12-12 | Fusemachines Inc. | Consilium Frontier Equity Fund LP | 15.9% | SCHEDULE 13G |
| 2025-12-12 | Fusemachines Inc. | Consilium Extended Opportunities Fund LP | 14.4% | SCHEDULE 13G |
| 2025-12-08 | Netcapital Inc. | GlobexUS Holdings, Corp. | 10.17% | SCHEDULE 13G |
| 2025-12-08 | Equillium, Inc. | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-08 | Immunic, Inc. | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-08 | Ovid Therapeutics Inc. | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-08 | Palatin Technologies Inc | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-08 | Palisade Bio, Inc. | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-08 | Pasithea Therapeutics Corp. | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-08 | Tenax Therapeutics Inc | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G |
| 2025-12-11 | Top Wealth Group Holding Ltd | L1 Capital Global Opportunities Master Fund, Ltd. | 9.99% | SCHEDULE 13G |
| 2025-12-11 | Xilio Therapeutics, Inc. | Coastlands Capital LP | 9.99% | SCHEDULE 13G |
| 2025-12-12 | Polyrizon Ltd. | Eli Zamir | 9.99% | SCHEDULE 13G |
| 2025-12-12 | Polyrizon Ltd. | L.I.A. Pure Capital Ltd. | 9.99% | SCHEDULE 13G |
| 2025-12-10 | Top Wealth Group Holding Ltd | Bigger Capital Fund L P | 9.97% | SCHEDULE 13G |
| 2025-12-08 | Cantor Equity Partners I, Inc. | Anson Funds Management LP | 9.9% | SCHEDULE 13G |
| 2025-12-08 | Velos Acquisition I Corp. f/k/a M3-Brigade Acquisition V Corp. | Anson Funds Management LP | 9.9% | SCHEDULE 13G |
| 2025-12-11 | Top Wealth Group Holding Ltd | Avondale Capital, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-11 | CXApp Inc. | Avondale Capital, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-12 | Perpetuals.com Ltd | Aldersgate Capital Partners Ltd. | 9.9% | SCHEDULE 13G |
| 2025-12-12 | Antelope Enterprise Holdings Ltd | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-12-12 | Arrive AI Inc. | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-12-11 | Jaguar Health, Inc. | Iliad Research & Trading, L.P. | 9.8% | SCHEDULE 13G |
| 2025-12-08 | Dbv Technologies S.A. | Janus Henderson Group Plc | 9.5% | SCHEDULE 13G |
| 2025-12-11 | SciSparc Ltd. | Ronen Fatal | 8.76% | SCHEDULE 13G |
| 2025-12-11 | SciSparc Ltd. | Eli Zamir | 8.76% | SCHEDULE 13G |
| 2025-12-12 | Silvia, Inc. | Jane Street Group, LLC | 8.6% | SCHEDULE 13G |
| 2025-12-11 | Quoin Pharmaceuticals Ltd. | Resolute Capital Asset Partners LLC | 8.5% | SCHEDULE 13G |
| 2025-12-08 | Assembly Biosciences, Inc. | Janus Henderson Group Plc | 8.2% | SCHEDULE 13G |
| 2025-12-09 | Chenghe Acquisition III Co. | Picton Mahoney Asset Management | 7.66% | SCHEDULE 13G |
| 2025-12-08 | Lantronix, Inc. | TL Stiftung | 7.6% | SCHEDULE 13G |
| 2025-12-11 | Proshares Trust | Samuel Patton Black IV | 7.6% | SCHEDULE 13G |
| 2025-12-11 | DENNY'S Corp | Glazer Capital, LLC | 7.38% | SCHEDULE 13G |
| 2025-12-10 | Cartesian Growth Corp III | Picton Mahoney Asset Management | 7.25% | SCHEDULE 13G |
| 2025-12-08 | SaverOne 2014 Ltd. | Liu Yi Ming | 7% | SCHEDULE 13G |
| 2025-12-10 | Belite Bio, Inc | Darwin Global Management, Ltd. | 7% | SCHEDULE 13G |
| 2025-12-12 | Cool Company Ltd. | Silver Point Capital, L.P. | 7% | SCHEDULE 13G |
| 2025-12-08 | Blue Water Acquisition Corp. III | Harraden Circle Investments, LLC | 6.63% | SCHEDULE 13G |
| 2025-12-10 | New America Acquisition I Corp. | Harraden Circle Investments, LLC | 6.62% | SCHEDULE 13G |
| 2025-12-11 | New America Acquisition I Corp. | Washington Muse Investments SPC for and on behalf of Heraclitus SP | 6.51% | SCHEDULE 13G |
| 2025-12-08 | Build-A-Bear Workshop, Inc. | Divisadero Street Capital Management, LP | 6.4% | SCHEDULE 13G |
| 2025-12-09 | Integral Ad Science Holding Corp. | Glazer Capital, LLC | 6.32% | SCHEDULE 13G |
| 2025-12-10 | Australian Oilseeds Holdings Ltd | Arena Investors LP | 6.3% | SCHEDULE 13G |
| 2025-12-11 | Proshares Trust | Christopher William Black | 6.2% | SCHEDULE 13G |
| 2025-12-10 | Hawaiian Electric Industries Inc | Arena Holdings Management LLC | 6.1% | SCHEDULE 13G |
| 2025-12-11 | Crescent Biopharma Inc | ForGrowth III PA B.V. | 6.1% | SCHEDULE 13G |
| 2025-12-08 | Ocugen, Inc. | Janus Henderson Group Plc | 6% | SCHEDULE 13G |
| 2025-12-08 | Bitcoin Infrastructure Acquisition Corp Ltd | Tenor Capital Management Company, L.P. | 6% | SCHEDULE 13G |
| 2025-12-08 | RLJ Lodging Trust | He Zhengxu | 5.9% | SCHEDULE 13G |
| 2025-12-09 | SilverBox Corp V | Tenor Capital Management Company, L.P. | 5.9% | SCHEDULE 13G |
| 2025-12-08 | Ocular Therapeutix, Inc | Summer Road LLC | 5.7% | SCHEDULE 13G |
| 2025-12-10 | Astria Therapeutics, Inc. | Glazer Capital, LLC | 5.53% | SCHEDULE 13G |
| 2025-12-10 | Core Scientific, Inc. | Citadel Securities GP LLC | 5.5% | SCHEDULE 13G |
| 2025-12-08 | Terawulf Inc. | Citadel Securities GP LLC | 5.4% | SCHEDULE 13G |
| 2025-12-10 | Virtus Convertible & Income Fund II | Advisors Asset Management, Inc. | 5.29% | SCHEDULE 13G |
| 2025-12-08 | Rithm Property Trust Inc. | Bay Pond Partners, L.P. | 5.1% | SCHEDULE 13G |
| 2025-12-08 | General Purpose Acquisition Corp. | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2025-12-08 | Solaris Energy Infrastructure, Inc. | Jane Street Group, LLC | 5.1% | SCHEDULE 13G |
| 2025-12-08 | Maui Land & Pineapple CO Inc | Valueworks LLC | 5.03% | SCHEDULE 13G |
| 2025-12-08 | Biomea Fusion, Inc. | Janus Henderson Group Plc | 5% | SCHEDULE 13G |
| 2025-12-09 | Neogenomics, Inc. | Millennium Management LLC | 5% | SCHEDULE 13G |
| 2025-12-09 | Sintx Technologies Inc | Gregg Richard Honigblum | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Download this data (CSV)86 rows, with sources. Free with an account.
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.